GC203 bụ ọgwụgwọ TIL ọhụrụ nke na-abụghị nke nje virus nke e mepụtara site na iji ikpo okwu mgbasa mkpụrụ ndụ DeepTIL® nke Juncell Therapeutics na ikpo okwu mgbanwe mkpụrụ ndụ NovaGMP®. DeepTIL® na-eme ka TILs sie ike nke na agaghị achọ njikọta IL-2 mgbe etinyere ya, ike nke ọgwụgwọ tupu oge eruo nwekwara ike ịdị ala. NovaGMP® na-agbanwe mkpụrụ ndụ T na arụmọrụ dị elu dịka nke Lentiviral vector n'ụzọ akụ na ụba. GC203 nwere interleukin-7 nke na-ejikọta onwe ya na membrane, nke nwere ike ịnọgide na-enwe ike nke mkpụrụ ndụ ebe nchekwa T, na-eme ka mkpụrụ ndụ ahụ ji alụso ọrịa ọgụ dị n'ime rụọ ọrụ ma zere nsí sistemu.
Ndị nchọpụta nwalere GC203 n'ahụ ndị ọrịa a chọpụtara na ha nwere kansa ovarian ugboro ugboro, na-enweghị njikọta nke ọgwụ IL-2 ma ọ bụ lymphopletion siri ike. Ebumnuche nke ọmụmụ ihe a bụ ịchọpụta nchekwa na irè nke ọgwụgwọ a. E debanyere ndị ọrịa 20 n'etiti 09/2021 na 01/2024 na nnwale otu etiti mepere emepe, ebe a na-enyocha ndị ọrịa 18. Ndị ọrịa a na-enyocha nwere ECOG PS nke 1 (55.6%) ma ọ bụ 2 (44.4%) ma nata ọgwụgwọ sistemu ise gara aga (oke: 2-11). Ndị ọrịa 9 (50%) nwere ọnya etuto atọ ma ọ bụ karịa. Ọnụọgụ ọnya ahụ dị n'etiti bụ 57 (oke: 13-146) mm.
GC203 gosiri nsonaazụ dị mma n'ahụ ndị ọrịa nwere kansa ovarian ugboro ugboro ma ọ bụ nke na-eme ka ha gbasaa. E mezigharịrị profaịlụ nchekwa nke ọma ma e jiri ya tụnyere ọgwụgwọ TIL nkịtị, n'ihi obere ọgwụgwọ tupu oge eruo na mwepụ nke njikọta IL-2. Ọtụtụ n'ime ihe ndị na-adịghị mma (AEs) bụ ọkwa 1 ma ọ bụ ọkwa 2 ma enwere ike ibelata ma ọ bụ gwọọ ya site na ọgwụgwọ mgbaàmà. Enweghị ihe omume ọkwa 5 mere. Ka ọ na-erule ụbọchị njedebe nke 01/2024, ọnụego nzaghachi ebumnuche (ORR) nke onye nyocha nyochara bụ 33.3% (95% CI: 16.3 – 56.3), gụnyere 11.1% Mmeghachi omume zuru oke (CR). Ọnụego Njikwa Ọrịa (DCR) bụ 83.3% (95% CI, 60.8 – 94.2). Ọnụego Nlanarị (OS) nke ọnwa 12 bụ 68.8% (95% CI: 49.3 – 95.9). OS etiti ezughị oke dịka mbepụ data.
N'afọ 2023, a kpọgara Oriakụ H n'ụlọ ọgwụ n'afọ 2023 n'ihi nsogbu akwara afọ.na ihe mgbu n'úkwùMgbe a nyochachara ya, achọpụtara na ọtụtụ mkpụrụ ndụ lymph buru ibu n'ime retroperitoneum, úkwù, na ebe ndị ọzọ, nke gosiri na ọ nwere kansa ovarian dị elu. Ya mere, Oriakụ H mere chemotherapy, ịwa ahụ, immunotherapy, wdg, mana mmetụta ya adịghị mma, etuto ahụ wee maliteghachi.
Ya mere, Oriakụ H sonyere na nnwale ahụike nke ọgwụgwọ mkpụrụ ndụ TIL GC203, mgbe otu ọnwa nke ọgwụgwọ ya na GC203 gasịrị, etuto ahụ belatara site na 37.3%.
Mmechi: Ntinye nke GC203nwere nchekwa a na-anabata nke ọma ma dị irè nke ukwuu n'ime ndị ọrịa OC na-emegharị ugboro ugboro bụ ndị nwere oke nhọrọ ọgwụgwọ.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Ntụaka
1.https://www.juncell.com/academic-achievements
2.https://www.juncell.com/company-news-76
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5552
4.http://myimm.net/mianyizhiliao/2037.html
Oge ozi: Disemba-11-2024